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Abstract 
Background: Hemoperfusion through a column containing polymyxin B-immobilized fiber (PMX-HP) is beneficial in 
abdominal sepsis. We assessed the effects of PMX-HP in a model of severe Pseudomonas aeruginosa pneumonia.
Methods: Eighteen pigs with severe P. aeruginosa pneumonia were mechanically ventilated for 76 h. Pigs were ran-
domized to receive standard treatment with fluids and vasoactive drugs, or standard treatment with two 3-h PMX-HP 
sessions. Antibiotics against P. aeruginosa were never administered. We assessed endotoxemia through the endotoxin 
activity assay (EA). We measured the static lung elastance, ratio of arterial partial pressure per inspiratory fraction of 
oxygen (PaO2/FIO2), mean arterial pressure, cardiac output, systemic vascular resistance and inotropic score. Finally, 
every 24 h, we assessed complete blood count.
Results: In comparison with the control group, PMX-HP decreased percentage of circulating neutrophils from 
47.4 ± 13.8 to 40.8 ± 11.5 % (p = 0.009). In a subgroup of animals with the worst hemodynamic impairment, EA in the 
control and PMX-HP groups was 0.50 ± 0.29 and 0.29 ± 0.14, respectively (p = 0.018). Additionally, in the control and 
PMX-HP groups, static lung elastance was 26.9 ± 8.7 and 25.3 ± 7.5 cm H2O/L (p = 0.558), PaO2/FIO2 was 347.3 ± 61.9 
and 356.4 ± 84.0 mmHg (p = 0.118), mean arterial pressure was 81.2 ± 10.3 and 81.6 ± 13.1 mmHg (p = 0.960), car-
diac output was 3.30 ± 1.11 and 3.28 ± 1.19 L/min (p = 0.535), systemic vascular resistance was 1982.6 ± 608.4 and 
2011.8 ± 750.0 dyne/s/cm¯5 (p = 0.939), and inotropic score was 0.25 ± 0.10 and 0.26 ± 0.18 (p = 0.864).
Conclusions: In mechanically ventilated pigs with severe P. aeruginosa pneumonia, PMX-HP does not have any valu-
able clinical benefit, and studies are warranted to fully evaluate a potential role of PMX-HP in septic shock associated 
with severe pulmonary infections.
Keywords: Lung—endotoxemia, Intensive care—pulmonary, Complications—septicemia, Infection—bacterial
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Bacterial endotoxin is a crucial component of the outer 
membrane of Gram-negative bacteria. During the course 
of an infection, the lipid A component of the molecule 
is released by bacteria that duplicate or die [1]. This acti-
vates a vivid inflammatory response by the host immuni-
tary system and plays a crucial role in the development of 
sepsis and associated organ failure. Indeed, administra-
tion of endotoxin in healthy humans increases circulating 
cytokines and activates coagulation and complement path-
ways, mimicking the classical clinical signs of sepsis [2, 3].
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In the latest decade, there has been an increasing inter-
est in selective removal of endotoxin from blood to reduce 
the burden of sepsis [1, 4]. In particular, polymyxin B is 
an antibiotic with the attractive ability to bind and inac-
tivate endotoxin. Yet, the systemic use of this drug is lim-
ited by the associated neurotoxicity and nephrotoxicity. 
In the 1990s, a novel affinity column, characterized by 
polymyxin B, covalently immobilized to a polystyrene-
derived fiber, was developed in Japan [5]. When blood 
passes through this column, via an extracorporeal cir-
cuit, endotoxin is efficiently cleared, with no detectable 
polymyxin B in the elute [6]. In a pilot trial [7] in septic 
patients, hemoperfusion through the column containing 
polymyxin B-immobilized fiber (PMX-HP) produced a 
significant improvement in hemodynamic parameters. In 
the EUPHAS trial [8], 64 patients were treated, following 
abdominal surgery, with two 2-h sessions of PMX-HP. The 
28-day absolute risk of death improved from 53 to 32 % 
(p =  0.03). Conversely, in a recently completed trial [9], 
patients who underwent surgical procedures for abdomi-
nal infections were randomized to standard or PMX-HP 
treatment. PMX-HP was not associated with any survival 
benefit, and it did not reduce risks for developing organ 
failures. Importantly, in both studies only patients with 
abdominal sepsis, who promptly underwent surgery to 
control the primary source of infection, were enrolled. 
Thus, PMX-HP was primarily aimed at clearing the resid-
ual circulating endotoxin.
Besides the effects of PMX-HP on sepsis-associated 
cardiovascular dysfunction, a few investigators have 
suggested that PMX-HP could also improve pulmonary 
function in exacerbated idiopathic pulmonary fibrosis 
[10], interstitial pneumonia [11] and acute lung injury 
(ALI) [12–15]. In particular, patients with pulmonary 
comorbidities, hospitalized for prolonged periods or 
undergoing invasive mechanical ventilation (MV) pre-
sent the greatest risks for developing pneumonia by 
Gram-negative pathogens [16–18]. Yet, to date there is 
a lack of evidence on the potential benefits of PMX-HP 
in the early stages of severe Gram-negative pneumonia. 
Thus, we designed a prospective randomized trial in pigs 
with severe Pseudomonas aeruginosa and on MV for 76 h 
to examine whether PMX-HP would reduce endotoxin 
activity (EA) and consequently improve hemodynamic, 
pulmonary and clinical variables.
Methods
The study protocol was approved by the Animal Exper-
imentation Ethics Committee of the University of 
Barcelona. Animals were managed according to the Dec-
laration of Helsinki conventions for the use and care of 
animals.
Study animals, handlings, end of the study
Eighteen Large White–Landrace female pigs (weight 
32.8  ±  2.9  kg) were induced [19], intubated and con-
nected to a mechanical ventilator (SERVO-I, Maquet, 
NJ, USA). Anesthesia was maintained with a continu-
ous infusion of midazolam, 0.2–0.8  mg/kg/h, and fen-
tanyl, 5–10  µg/kg/h, in order to maintain cessation of 
spontaneous movements following painful stimulation. 
Pigs were ventilated in volume control, tidal volume 
10  mL/kg, positive end-expiratory pressure (PEEP) 
and respiratory rate adjusted to maintain gas exchange 
within the physiologic range. Inspiratory gases were 
conditioned through a heated humidifier (Con-
chatherm III, Hudson RCI, Temecula, CA). Throughout 
the study, lactated Ringer’s and 0.9  % NaCl solutions 
in a 1:1 ratio were administrated at 0.5–3  mL/kg/h. 
Ceftriaxone was administered to prevent pulmonary 
endogenous colonization. The femoral artery was can-
nulated for systemic arterial pressure monitoring and 
collection of blood samples. As previously described 
[19], we inserted a Swan–Ganz catheter into the jugu-
lar vein to monitor pulmonary artery pressure (PAP), 
central venous pressure (CVP), pulmonary artery 
wedge pressure (PCWP), core blood temperature and 
cardiac output (CO). A Foley catheter was introduced 
into the bladder to monitor urinary output. Animals 
were euthanized after 76  h of invasive MV or when 
severe respiratory or hemodynamic instability was sus-
tained, irrespective of maximal ventilatory (inspira-
tory fraction of oxygen of 1 and PEEP ≥15  cm H2O) 
or hemodynamic support (fluid challenge ≥1.5  L and 
norepinephrine ≥3 µg/kg/min). Upon autopsy, we took 
a tissue sample from each lobe for quantitative culture 
[20].
Model of severe P. aeruginosa pneumonia
As previously described [21], after surgical prepara-
tion and stabilization, 15  mL of a 108 colony-forming 
unit (cfu)/mL suspension of P. aeruginosa ATCC 27853 
was inoculated through sequential insertion of a bron-
choscope into the main right upper, medium and lower 
bronchi and the main left upper and lower bronchi. Per 
each bronchus, the bacterial suspension was slowly 
instilled over 30 s. This model is characterized by severe 
impairment of pulmonary function and mortality of 66 % 
before the end of the 72-h study [21]. Thus, to improve 
survival and ensure both PMX-HP treatments, we 
slightly modified the original ventilatory settings. In par-
ticular, in comparison with the aforementioned study, we 
decreased the tidal volume from 15 to 10 mL/kg and we 
applied PEEP. We never administered antibiotics active 
against P. aeruginosa. Blood was cultured daily.
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Randomization
After bacterial inoculation, pigs were randomized into 
the following groups through a computer-generated ran-
dom numbers using block randomization, with a fixed 
block length of 18 animals:
Control group: Standard treatment to sustain hemo-
dynamic stability, according to the surviving sepsis 
campaign guidelines [22], was applied. In particular, 
crystalloids (sequential fluid challenges of 250  mL) and 
norepinephrine (0.2–3  µg/kg/min) were administered 
to achieve a mean arterial pressure (MAP) ≥65 mm Hg; 
urine output ≥0.5 m/kg/h and mixed venous oxygen sat-
uration (SvO2) ≥65 %.
Treatment group: During surgical preparation, an 11-Fr 
dual lumen catheter (Fresenius Medical Care España, 
S.A., Madrid, Spain) was inserted into the femoral vein. 
As detailed above, standard treatment was applied. 
Additionally, after 24 and 48  h from pulmonary bacte-
rial challenge, PMX-HP was performed for 3  h through 
a veno-venous, pump-driven, extracorporeal system 
(EstorFLOW®, Estor, Milan, Italy) and a column contain-
ing polymyxin B-immobilized fiber (Toraymyxin, Toray 
Medical Co., Ltd, Tokyo, Japan). Additional file 1: Figure 
S1 depicts experimental settings during PMX-HP. Blood 
flow through the column was maintained between 80 and 
100 mL/min. During the procedure, heparin was contin-
uously administered and adjusted to prolong the partial 
thromboplastin time (PTT) 1.5–2.0 times the mean con-
trol value.
Endotoxin activity assay
The EA assay was measured every 12  h and after each 
PMX-HP, as previously described [23, 24]. The assay 
measures EA, based on whole blood neutrophil chemi-
luminescence activity (on a scale from 0 to 1). EA was 
assayed in duplicate, and samples were considered ade-
quate if the coefficient of variation between duplicates 
was lower than 30 %. As detailed in the Additional file 2: 
Appendix, we performed preliminary studies to estimate 
endotoxin concentration in pig blood, based on the EA. 
Thus, as predicted by the regression analysis reported in 
the Additional file 2: Appendix, EA level of 0 is equivalent 
to P. aeruginosa endotoxin concentration of 0  pg/mL, a 
level of 0.4–350.15 pg/mL and a level of 0.6–1361.36 pg/
mL.
Respiratory measurements
Every 24 h, airway and esophageal pressures and respira-
tory flow rates were measured and recorded [20]. The 
static lung elastance was computed using standard for-
mulae [20].
Hemodynamic measurements and gas exchanges
Every 12  h, gas exchange (arterial and mixed venous 
blood), MAP, CVP, mean PAP, PCWP and CO were 
measured. Stroke volume (SV), systemic vascular resist-
ance (SVR), pulmonary vascular resistance (PVR), venous 
admixture, venous-to-arterial partial pressure carbon 
dioxide difference (Pv-aCO2) and fluid balance were 
computed. As previously reported [8], we computed the 
inotropic score and the vasopressor dependency index.
Clinical variables
Every 24  h, we assessed complete blood count, body 
temperature, coagulation parameters and alanine 
transaminase.
Statistical analysis
Continuous variables were described as means and 
standard deviations, unless otherwise specified. Cat-
egorical variables were described as frequencies and 
percentages. Continuous variables were analyzed using 
a restricted maximum likelihood analysis, based on 
repeated measures approach, including the independ-
ent ‘treatment’ variable, the repeated ‘time of assess-
ment’ variable and their interaction as factors. Per each 
model, normality of residuals was confirmed through 
visual inspection of residuals distribution. A compound 
symmetry (co)variance structure was used to model 
the within-subject errors. Each pairwise comparison 
was corrected using Bonferroni’s test, in order to con-
trol for the experiment-wise error rate. All reported p 
values are the exact p values derived through a permu-
tation test. A two-sided p value ≤0.05 was considered 
statistically significant. All statistical analyses were per-
formed using SAS software (version 9.2; SAS Institute, 
Cary, NC).
Results
Nine animals were enrolled into the control group and 
eight into the treatment group. One animal of the treat-
ment group was euthanized after 9  h for surgical com-
plications, and it was excluded from the final analysis. 
Additionally, one control animal was euthanized after 
64  h of MV for severe respiratory instability. Finally, in 
one treatment animal, the study was terminated after 
62  h of MV, due to accidental extubation. In the treat-
ment and control group, lung tissue P. aeruginosa con-
centration was 3.65  ±  1.01 and 3.90  ±  1.54  log  cfu/g, 
respectively (p  =  0.341). P. aeruginosa bacteremia was 
found only in one control animal. Analysis of the worst 
clinical parameters recorded within the first 24 h of the 
study is reported in Table  1. No significant differences 
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were found, corroborating similar clinical conditions 
before study treatments.
Hemodynamics
Figure  1 depicts dynamics of key hemodynamic param-
eters between study groups. There was a significant 
change over time—similar in both groups—in heart 
rate (p  <  0.001), the vasopressor dependency index 
(p =  0.030), the inotropic score index (p =  0.028), pul-
monary vascular resistance (p  =  0.028), the Pv-aCO2 
(p  <  0.001) and the fluid balance (p  =  0.048), whereas 
there were no effects associated with the use of PMX-
HP, no significant change over time and no significant 
interaction between treatment in respect of the extrac-
tion ratio, the oxygen consumption and delivery. In all 
animals, after bacterial challenge, the median decrease 
in MAP, within 24  h, was 9.89  % (range 1.36–20.6  %) 
(Additional file  1: Figure S2). Post hoc analysis of only 
animals with the most significant hemodynamic impair-
ment—characterized by a drop in MAP greater than 
Table 1 Analysis of worst clinical parameters, within 24 h from bacterial inoculation
We report analyses of worst clinical parameters (within 24 h from bacterial challenge) to confirm the presence of pneumonia and investigate potential baseline 
differences between study groups. Data are reported as mean ± standard deviation
MV mechanical ventilation, WBC white blood cell
PIG N. Highest heart rate 
within 24 h from bac-
terial challenge 
(beats/min)
Baseline mean arte-
rial pressure (mm Hg)
Greatest mean arte-
rial pressure drop 
within 24 h from bac-
terial challenge (%)
Highest body tem-
perature within 24 h 
from bacterial chal-
lenge (°C)
Highest WBC 
within 24 h from bacte-
rial challenge (µL−1)
Control group (9 
animals)
86 ± 22 82.1 ± 7.2 11.4 ± 3.4 39.5 ± 0.9 21,544 ± 6323
Treatment group (8 
animals)
95 ± 23 78.5 ± 11.2 9.7 ± 8.9 40.0 ± 0.6 16,162 ± 4785
p value 0.402 0.438 0.630 0.188 0.069
Fig. 1 Differences in most significant hemodynamic parameters, between the control and treatment group. a Central venous pressure signifi-
cantly differed between groups (p < 0.001) and changed over time (p < 0.001), without interactions between study groups and time of assessment. 
Similarly, pulmonary arterial pressure (b) significantly differed between groups (p = 0.006) and significantly changed over time (p < 0.001). There 
were no significant differences between study groups, no significant changes over time and no interactions between study groups and time of 
assessment in mean arterial pressure (c); cardiac output (d); systemic vascular resistance (e); and mixed venous oxygen saturation (f). *Polymyxin 
B-immobilized fiber hemoperfusion was carried out for 3 h
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10 %—is depicted in Table 2. Still, in this specific popu-
lation, comparisons between study groups did not show 
any substantial difference in hemodynamic, pulmonary 
and clinical variables. 
Endotoxin clearance
As depicted in Fig.  2a, PMX-HP, in comparison with 
standard treatment, had no effects in the endotoxin 
removal. Of note, blood EA raised recurrently in both 
groups, specifically after 36  h of MV, and at the end of 
the study. Nevertheless, subgroup analysis of only ani-
mals with the most significant hemodynamic impact 
(Fig. 2b) showed a significant reduction in blood EA from 
0.50  ±  0.29 in the control group to 0.29  ±  0.14 in the 
PMX-HP group (p = 0.018).
Clinical and pulmonary parameters
Figure  3 depicts clinical and pulmonary parameters 
throughout the study time. PMX-HP significantly 
decreased white blood cells (WBC) count and plate-
let counts. Furthermore, there was a significant change 
over time—similar in both groups—in body temperature 
(p  <  0.001) and hemoglobin (p  <  0.001), whereas there 
were no effects associated with the use of PMX-HP, no 
significant change over time and no significant inter-
action between treatment and time of assessment, in 
respect of prothrombin time, activated partial thrombo-
plastin time and creatinine. Finally, alanine transaminase 
was 29.7 ±  9.8 and 34.6 ±  7.8  IU/L in the control and 
treatment group, respectively (p  =  0.006), without sig-
nificant changes over time, and no interactions between 
Table 2 Hemodynamic, pulmonary and  clinical variables in  animals with  a drop in  mean arterial pressure ≥10  %, 
within 24 h from bacterial inoculum
Of note, only animals with a decrease in mean arterial pressure ≥10 %, within 24 h from bacterial inoculum, were included in this post hoc analysis
Italics p values indicate statistically significant differences between study groups
Hb hemoglobin, PaCO2 arterial partial pressure of carbon dioxide, PaO2/FiO2 ratio of partial pressure arterial oxygen and fraction of inspired oxygen, Pv-aCO2 venous-
to-arterial partial pressure carbon dioxide difference
Group p value
Control (six animals) Treatment (five animals)
Hemodynamic variables
Heart rate (beats/min) 66.7 ± 18.6 75.0 ± 22.0 0.031
Central venous pressure (mm Hg) 7.7 ± 3.8 7.9 ± 2.7 0.653
Mean arterial pressure (mm Hg) 77.6 ± 8.3 77.9 ± 11.5 0.814
Mean pulmonary arterial pressure (mm Hg) 20.8 ± 4.7 21.5 ± 4.7 0.388
Cardiac output (L/min) 3.3 ± 1.1 3.6 ± 1.2 0.245
Systemic vascular resistance (dyne/s/cm5) 1837.2 ± 593.5 1703.4 ± 567.9 0.252
Pulmonary vascular resistance (dyne/s/cm5) 299.9 ± 127.6 274.5 ± 113.9 0.159
Vasopressor dependency index 0.25 ± 0.10 0.30 ± 0.17 0.385
Mixed venous saturation (%) 61.9 ± 11.4 60.3 ± 0.10 0.164
Pv-aCO2 8.52 ± 3.38 8.78 ± 3.15 0.678
Fluid balance (mL) −48.9 ± 445.2 −73.5 ± 501.9 0.842
Pulmonary variables
PaO2/FiO2 353.8 ± 55.3 340.4 ± 81.8 0.792
PaCO2 40.3 ± 4.2 40.7 ± 4.5 0.598
Lung elastance (cm H2O/L) 27.7 ± 9.2 25.3 ± 8.2 0.477
Pulmonary shunt (%) 8.8 ± 4.2 9.2 ± 4.1 0.635
Clinical variables
Temperature (°C) 38.3 ± 1.2 39.0 ± 1.1 <0.001
White blood cells (cells/µL) 17.9 ± 6.8 13.7 ± 5.0 0.004
Neutrophils (%) 45.6 ± 14.6 42.5 ± 12.9 0.364
Lymphocytes (%) 46.1 ± 14.8 50.4 ± 13.3 0.234
Monocytes (%) 2.5 ± 1.2 3.3 ± 2.8 0.631
Hb (g/dL) 8.6 ± 1.2 8.2 ± 1.5 0.290
Platelet (cells/mm3) 255.0 ± 61.8 258.2 ± 115.1 0.741
Creatinine (mg/dL) 0.99 ± 0.2 1.3 ± 1.4 0.154
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study groups and time of assessment. As for additional 
pulmonary parameters, arterial partial pressure of car-
bon dioxide significantly increased during the study time 
(p  =  0.001), without differences between study groups, 
while there were no significant differences between study 
groups, no significant changes over time, and no interac-
tions between study groups and time of assessment in 
lung elastance.
Discussion
This study shows that in pigs with severe, untreated, P. 
aeruginosa pneumonia, PMX-HP decreases circulating 
neutrophils and only in animals with the most significant 
hemodynamic impairment after bacterial challenge, it 
significantly reduces blood endotoxin, but with no other 
benefits on hemodynamic and pulmonary parameters.
Up to the present time, PMX-HP has been primar-
ily used in surgical patients with intra-abdominal sepsis. 
In 2009, the EUPHAS trial [8] demonstrated a survival 
benefit in patients with abdominal sepsis treated with 
surgery and PMX-HP. The study was designed to evalu-
ate whether the use of PMX-HP could improve hemody-
namic stability and decrease vasopressor requirements. 
At the first interim analysis, a significant survival benefit 
was found, and thus the study was terminated earlier. 
Yet, it is important to emphasize that the study was likely 
underpowered to show any reduction in mortality, which 
was obtained after adjustment for the sepsis-related 
organ failure assessment score. Also, the very high mor-
tality rate in the control group limited the possibility to 
translate these findings into other intensive care unit 
populations. A later study by Puyen et al., in patient with 
peritonitis due to gut or biliary tract perforation, was 
specifically designed to detect differences in 28-day mor-
tality, but a mortality rate of 27.7 and 19.5 % was found in 
the treatment and control group, respectively (p = 0.14). 
In an ongoing American trial (Evaluating the Use of Poly-
myxin B Hemoperfusion in a Randomized Controlled 
Trial of Adults Treated for Endotoxemia and Septic Shock 
(EUPHRATES), ClinicalTrials.Gov NCT01046669) [25], 
all patients with septic shock, irrespective of the source 
of infection, and EA ≥0.60 units are being treated with 
PMX-HP or standard treatment. Finally, in a recent Japa-
nese retrospective propensity-matched analysis, post-
operative polymyxin B hemoperfusion did not show any 
survival benefit in patients with abdominal septic shock 
[26]. Thus, it is important to emphasize that our labora-
tory study is the first that specifically assessed the effects 
of PMX-HP on severe P. aeruginosa pulmonary infection.
In our main analysis, PMX-HP did not decrease EA. 
Yet, post hoc analyses in a subset of animals with the 
worst decrease in MAP found a significant reduction in 
EA with the use of PMX-HP. Theoretically, these were the 
animals that could have benefited the most by endotoxin 
Fig. 2 Endotoxin activity in the control and treatment group during study time. Data are reported as mean and standard error. Polymyxin 
B-immobilized fiber hemoperfusion was carried out for 3 h, after 30 and 50 h. a Endotoxin activity in all subjects. Group effect, p = 0.224; study time 
effect, p = 0.882; group * study time effect, p = 0.572. b Post hoc analysis in only animals with a decrease in mean arterial pressure ≥10 %, within 
24 h from bacterial challenge. Group effect, p = 0.018; study time effect, p = 0.473; group * study time effect, p = 0.830
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clearance, but this did not result in any valuable clinical 
improvement. Our results are in contrast to previous 
findings obtained from different animal models of sep-
tic shock [1]. The lack of severe cardiovascular dysfunc-
tion and tissue hypoperfusion found in our model, likely 
due to a compartmentalization of the infection, and swift 
hemodynamic support, could partially explain our nega-
tive findings. Indeed, as depicted in Fig. 1, after bacterial 
challenge, systemic vascular resistances decreased within 
the first 36 h, although not significantly, but there was a 
concomitant increase in central venous pressure, driven 
by rapid resuscitation with crystalloids and vasoactive 
drugs. Another potential reason is that in our model 
pulmonary pathogens constituted a continuous source 
of endotoxin. Conversely, in the majority of above-men-
tioned clinical studies, PMX-HP was applied following 
surgical control of the primary source of infection, and 
it was primarily aimed at clearing the residual circulat-
ing endotoxin. In our settings, we applied PMX-HP for 
3 h, for two subsequent days. In an interesting recent trial 
[27], sequential estimation of PT-international normal-
ized ratio (INR) was a strong predictor of the efficacy of 
treatment. Additionally, exacerbation of PT-INR (>0.16) 
before a second PMX-HP session was the most important 
predictor for 28-day mortality and futility of treatment. 
In our settings, we did not focus specifically on PT-INR. 
Yet, we can speculate that two sessions of PMX-HP may 
have not been sufficient to control the sustained surge of 
endotoxin from the lungs. Also, we might have started 
treatment relatively late, given that the first PMX-HP ses-
sion started 24 h after the extensive bacterial challenge. 
Finally, given the most recent findings [28, 29] on patho-
gen-associated molecular patterns, endogenous alarmins 
and the host response through toll-like receptors, it could 
be argued that clearance of endotoxin could only have a 
limited impact on the complexity of severe respiratory 
Gram-negative infections.
In line with previous studies [11, 30, 31], we found a sig-
nificant reduction of WBC, specifically neutrophils. Dur-
ing PMX-HP treatment, neutrophils bind with endotoxin, 
Fig. 3 Differences in laboratory parameters and oxygenation parameters between the control and treatment group. a Total white blood cells 
count (a) (p = 0.031) differed between study groups, without significant changes over time, and no interactions between study groups and time 
of assessment; while percentage of neutrophils (b) differed between study groups (p = 0.009), significantly changed over time (p < 0.001), without 
interactions between study groups and time of assessment; similarly, percentage of lymphocytes (c) differed between study groups (p = 0.002), 
significantly changed over time (p < 0.001), without interactions between study groups and time of assessment; also, platelets count (d) differed 
between study groups (p < 0.001), significantly changed over time (p < 0.001), without interactions between study groups and time of assess-
ment. Ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/FiO2) (e) and pulmonary shunt (f) significantly changed over 
time (p < 0.001 and p = 0.018, respectively), in a similar fashion between groups, and without interactions between study groups and time of 
assessment. Of note, hemoperfusion through a column containing polymyxin B-immobilized fiber caused a significant reduction in circulating 
neutrophils and platelets and an increase in circulating lymphocytes
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and then the endotoxin–neutrophil complex attaches 
to polymyxin [4]. Theoretically, this could provide some 
advantages during the course of sepsis, since the reduc-
tion in activated inflammatory cells could hinder the 
inflammatory cascade. Yet, polymorphonuclear leuko-
cytes provide the front line of host defense and substantial 
removal could also facilitate the establishment or persis-
tence of the infection. Furthermore, we found a signifi-
cant decrease in platelets count, due to their absorption 
and consumption through the hemoperfusion column; 
nevertheless, this was not associated with any complica-
tion. Also, it should be highlighted that neither bleeding 
nor systemic and circuit clotting occurred with the use of 
PMX-HP.
Some investigators implied that PMX-HP could be use-
ful in patients with severe pulmonary inflammations. 
During severe pulmonary bacterial infection, endotoxin 
induces a vast production of interleukin 8, which acts as 
a chemo-attractant. As a result, neutrophils migrate into 
the pulmonary interstitial space releasing inflammatory 
mediators. This drastically impairs the alveolar-capillary 
barrier and pulmonary function [32, 33]. In a previous 
study in rats, challenged intratracheally with endotoxin 
[34], PMX-HP reduced pulmonary chemotaxis and 
improved microcirculation, vascular permeability and 
oxygenation. In other clinical studies in patients with sep-
sis, mainly caused by pulmonary sources, investigators 
found a drastic decrease in the activation of chemokines, 
neutrophils and vascular endothelial cells with PMX-HP 
[13, 35], as a result pulmonary function improved. In the 
present study, we did not find any improvement in PaO2/
FiO2 between groups. This was likely related to the lack of 
PMX-HP efficacy on endotoxin clearance. Additionally, it 
is important to consider that the pulmonary inflamma-
tory cascade and neutrophils migration is a highly regu-
lated mechanism that requires time to be modulated [13]; 
thus, even if we found a significant decrease in circulat-
ing neutrophils, we may have missed any improvement in 
pulmonary function, due to the limited duration of our 
study.
There are a few limitations to our study. First, we 
developed severe pneumonia in previously healthy and 
young animals. Thus, in comparison with the clinical 
scenario, we may have underestimated the pulmonary 
and hemodynamic response to pneumonia; addition-
ally, we may have also undervalued the clinical ben-
efit of PMX-HP in septic patients with comorbidities. 
Second, upon autopsy, we did not perform histology 
studies; thus, we may have missed significant addi-
tional benefits associated with clearance of pulmonary 
endotoxin. Third, as shown in Additional file  2, we 
found a mildly variable association between EA and P. 
aeruginosa or E. coli blood endotoxin concentration. 
Importantly, following formation of endotoxin–anti-
body complexes the assay utilizes polymorphonu-
clear leukocytes’ chemiluminescence to compute the 
EA [23]. Previous laboratory studies corroborated the 
applicability of the EA assay for the measurement of 
endotoxin in canine blood samples [36]. Yet, in pig’s 
blood, the oxidant release by neutrophils and the 
resulting light emission could vary in comparison with 
humans. Thus, the absolute values of endotoxin con-
centration and EA of our study are useful, but must 
be interpreted with caution. Additionally, it should 
be emphasized that some investigators recently ques-
tioned the reliability of EA assay in humans versus 
older methods, such as the limulus amebocyte lysate 
assay [37]. Fourth, during acute stresses, release of 
quiescent endotoxin into the bloodstream by endog-
enous Gram-negative flora of the gastrointestinal tract 
is substantial in humans [38–41]. This may not be rel-
evant in pigs with pneumonia and could have further 
underestimated the effects of PMX-HP. Fifth, in the 
present study, and in previous similar studies in septic 
pigs [42], the infection was untreated. This was aimed 
at studying the effects of PMX-HP in a scenario of sus-
tained infection and consistent high level of endotox-
emia. Yet, in clinical settings, antibiotic-induced release 
of endotoxin from pathogens could be significant [43, 
44], particularly during the first hours of antimicrobial 
treatment. Consistently, in previous positive clinical 
study [8], patients were treated with antibiotics—fol-
lowing abdominal surgery—and PMX-HP helped clear-
ing the residual endotoxin. Thus, we cannot fully reject 
the synergistic effects of PMX-HP in treated patients, 
which should be further evaluated in future investiga-
tions. Finally, our study lacks of a control group with-
out pulmonary bacterial challenge. This additional 
group could have further increased the scientific value 
of the study and comparisons among groups.
Conclusions
In conclusion, we showed that in pigs with severe 
untreated P. aeruginosa pneumonia, PMX-HP does not 
improve the early management of the severe infection. 
Confirmation of these important negative findings in 
different animal species and in humans is warranted, to 
corroborate the no benefits associated with the use of 
PMX-HP in severe Gram-negative pulmonary infections.
Additional files
Additional file 1. Supplementary figures.
Additional file 2. Appendix: Preliminary studies to evaluate the applica-
bility of the Endotoxin Activity AssayTM to measure endotoxin activity in 
pig whole blood.
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